Alumis' Phase 3 Psoriasis Data Reinforce Efficacy but Leave Competitive and Financial Risks Unchanged

What happened

Alumis announced late-breaking Phase 3 data at AAD showing envudeucitinib delivers early and robust skin clearance and quality-of-life improvements in plaque psoriasis, supporting its potential as a leading oral therapy. This update confirms the drug's competitive efficacy profile, but the market had already priced in success after earlier topline data drove the stock from ~$5 to $24.17. However, the data do not address key commercial vulnerabilities, including twice-daily dosing versus once-daily competitors like Takeda's zasocitinib and J&J's icotrokinra. Moreover, with no product revenue, ~$400M annualized cash burn, and reliance on future capital raises, Alumis remains a high-risk, pre-commercial biotech. Thus, while the news is positive, it does not materially alter the investment landscape at current elevated valuations.

Implication

The Phase 3 data strengthen envudeucitinib's case for psoriasis approval and a 2H26 NDA submission, aligning with prior expectations. However, they fail to mitigate core concerns: twice-daily dosing limits convenience against rivals, long-term safety beyond 24 weeks is unknown, and intense competition could erode market share. At a ~$2.5B market cap, the stock embeds significant success, leaving little margin of safety given the high cash burn and binary outcomes. Investors should consider trimming positions above $28 or waiting for a pullback to $17, as per the DeepValue report's guidance. Upcoming catalysts, like detailed safety data and lupus Phase 2b results, add volatility but do not justify new buys at current levels.

Thesis delta

The new Phase 3 data validate envudeucitinib's efficacy as anticipated, but they do not address the competitive disadvantages or financial risks highlighted in the DeepValue report. Therefore, the investment thesis of a 'POTENTIAL SELL' with limited upside from current prices remains unchanged, as the stock already discounts approval success.